Spero Therapeutics, Inc. (SPRO): Nasdaq/NYSE listing notice — Spero Therapeutics receives Nasdaq bid price deficiency notice; has until Aug 25, 2025 to regain compliance

Spero Therapeutics, Inc.

Nasdaq notified Spero on Feb 25, 2025 that its stock closed below $1.00 for 30 consecutive trading days.
Compliance deadline is August 25, 2025; cure requires closing at $1.00+ for 10 consecutive business days.
If not cured, Spero may transfer to Nasdaq Capital Market and consider reverse stock split for 180-day extension.
Stock continues trading on Nasdaq GS under SPRO; no immediate delisting effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Spero Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

otifying the Company that, for the preceding 30 consecutive trading days, the closing bid price of its common stock was below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). At this current time, this Notice has no effect on the listing of the Company’s common stock, which continues to trade on the Nasdaq Global Select Market (“Nasdaq GS”) under the symbol “SPRO”.

View on SEC.gov

Browse all listing & compliance notices →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-042785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.